Liliya Sutherland, DO
Retina Specialist · Grand Rapids, MINPI 1942463252
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (50.4%), travel and lodging and ownership interests — rather than concentrated in one kind of arrangement. It is spread thinly across 19 manufacturers, the largest accounting for just 23.9%. Reporting peaked in 2024 at $3,842 and has fallen 79.9% since, to $774 in 2025.
Across 147 payments — averaging $90.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eyepoint US, Inc.$3K
- Alimera Sciences, Inc.$3K
- US Retina LLC$2K
- Spark Therapeutics, Inc.$2K
- Regeneron Healthcare Solutions, Inc.$976
- AbbVie$462
- plus $1K from 13 others
Across 17 payments — averaging $6845.28 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Neurotech Pharmaceuticals, Inc.$116K
What the payments were for
- Speaking & faculty fees$1,87514%
- Travel & lodging$2,36918%
- Food & beverage$6,71350%
- Ownership interest$2,35218%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eyepoint US, Inc. | 14 | $3,185 |
| Alimera Sciences, Inc. | 24 | $3,062 |
| US Retina LLC | 5 | $2,352 |
| Spark Therapeutics, Inc. | 4 | $1,918 |
| Regeneron Healthcare Solutions, Inc. | 29 | $976 |
| AbbVie(2 entities) | 17 | $462 |
| Apellis Pharmaceuticals, Inc. | 12 | $270 |
| Novartis | 7 | $221 |
| ANI Pharmaceuticals, Inc. | 6 | $177 |
| Mallinckrodt Enterprises LLC | 7 | $136 |
| Genentech USA, Inc. | 4 | $116 |
| Bausch & Lomb Americas Inc. | 5 | $106 |
| Astellas Pharma US Inc | 3 | $84 |
| Biogen | 4 | $83 |
| Hoffmann-la Roche Limited | 1 | $64 |
| Neurotech Pharmaceuticals, Inc. | 2 | $41 |
| Mallinckrodt Hospital Products Inc. | 1 | $22 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $19 |
| Amgen | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,309 in reported general payments places this provider in the 70th percentile of 52 retina specialist providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Difluprednate | 75 | $7,400 |
| Prednisolone Acetate | 171 | $5,561 |
| CombiganBrimonidine Tartrate/Timolol | 11 | $2,723 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 14 | $1,735 |
| Dorzolamide Hcl | 50 | $1,186 |
| Timolol Maleate | 68 | $730 |
| Brimonidine Tartrate | 44 | $690 |
| Acetazolamide | 19 | $495 |
| Gentamicin Sulfate | 57 | $481 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 16 | $439 |
| Latanoprost | 30 | $384 |
| MoxifloxacinMoxifloxacin Hcl | 33 | $334 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCombigan | $462 | $2,72311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 52 retina specialist providers in Michigan.
Other retina specialist in Grand Rapids
- Edward KorotGrand Rapids$44K
- Thomas AabergGrand Rapids$25K
- Nathan PezdaGrand Rapids$13K
- Greg BeverGrand Rapids$4K
- Alan MargherioGrand Rapids$0
- Jeremy WolfeRoyal Oak$809K
- Lisa FaiaRoyal Oak$520K
- Tarek HassanRoyal Oak$460K
- Asheesh TewariDearborn$204K
- Sandeep RandhawaRoyal Oak$94K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.